New Study Shows Improved Peritoneal Mesothelioma Survival

Patients with malignant peritoneal mesothelioma who completed a novel, two-stage cytoreduction and intraperitoneal chemotherapy regimen had a median overall survival of 6.65 years. Almost 30 percent of those patients had a survival estimate of more than 10 years after the second stage of treatment, according to a study published recently in the Annals of Surgical Oncology. The study involved 113 patients from New York-Presbyterian Hospital/Columbia University Medical Center. Researchers demonstrated the therapeutic advances concerning this once unbeatable cancer. While progress has been slow in improving current pleural mesothelioma treatments, research has shown more significant advances in novel therapies for the peritoneal type of the cancer. “There is hope out there for these [peritoneal] patients today,” Dr. Michael Kluger, assistant professor of surgery and leader of the mesothelioma program at Columbia’s medical center, told Asbestos.com. “People are living a long time now when they are appropriately treated from the get-go. It is night and day from where it once was.” Second Surgery Is Helpful The study objective was to determine the time and predictors of mesothelioma tumor recurrence in optimally treated patients. The median, recurrence-free survival was 38.5 months, and 80 percent of the patients with recurrence received some form of iterative treatment. “Even when there is recurrence, there is opportunity for retreatment of this...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Columbia University Medical Center Dr. Michael Kluger Dr. Paul Sugarbaker HIPEC for peritoneal mesothelioma New York-Presbyterian Hospital peritoneal mesothelioma treatment Source Type: news

Related Links:

The U.S. Food and Drug Administration moved closer on Tuesday to formulating standardized testing of talc-based products for the presence of toxic asbestos fibers. Experts from eight different federal agencies explained earlier recommendations at a day-long hearing. The session also featured input from 25 members of the public, which included industry representatives, consumer advocates and testing experts. “Standards are needed,” said Dr. Paul Howard, FDA Office of Regulatory Science, during his presentation. “They just don’t exist at this time.” Dr. Linda Katz, director of the FDA Office of ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ONCOS-102, a promising immunotherapy vaccine, is moving closer to becoming a part of future first-line treatment for mesothelioma. Early clinical trial results announced this week show safety and efficacy when the vaccine is used in combination with standard-of-care chemotherapy for patients with inoperable pleural mesothelioma. Targovax, a Scandinavian pharmaceutical company developing the drug, is moving forward with another study combining ONCOS-102 with a checkpoint inhibitor drug such as Keytruda (pembrolizumab) or Opdivo (nivolumab), along with chemotherapy. “We have seen enough data at this point to be going ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The purpose of the present review was to describe evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC), with cytoreductive surgery (CRS), in patients with a diagnosis of mesothelioma, appendiceal (including appendiceal mucinous neoplasm), colorectal, gastric, ovarian or primary peritoneal carcinoma. Relevant studies were identified from a systematic MEDLINE and EMBASE search of studies published from 1985 to 2019. Studies were included if they were RCTs. If no RCTs were identified, prospective and retrospecctive comparative studies (where confounders are controlled for studies with greater than ...
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
A team of experts from eight different federal agencies has presented the U.S. Food and Drug Administration with preliminary recommendations to standardize the testing of talc for the presence of asbestos and other potentially harmful mineral products. The recommendations, some of which reject long-held talc industry positions, are designed to end the discrepancies in analysis of whether talc products are contaminated with cancer-causing substances. Preliminary recommendations will be part of the FDA’s public meeting on Feb. 4 to discuss and obtain scientific information on testing for asbestos in talc-based products...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Publication date: Available online 3 January 2020Source: Seminars in Cancer BiologyAuthor(s): Kelly Olino, Tristen Park, Ntia AhujaAbstractAdvances in immunotherapy, most notably antibodies targeting the inhibitory immune receptors cytotoxic T-lymphocyte associated protein 4 (CTLA-4/CD152), programmed death protein 1 (PD-1/CD279) and programmed death-ligand 1 (PD-L1/B7H1/CD274) have become effective standard therapies in advanced malignancies including melanoma,1–4 merkel cell carcinoma5, urological cancers6–8, non-small cell lung cancer9–11, mis-match repair (MMR) deficient tumors12, and Hodgkin lymphoma...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Soltermann Malignant pleural effusion (MPE) is a severe condition of advanced tumors without effective therapy. We used digitalized immunohistochemical and transcriptional approaches to investigate the prognostic influence of immune cells and expression variance of associated immunomodulatory molecules in MPE. Cytology tissue microarrays were constructed from MPE cell blocks of 155 patients with five tumor entities. Immune cells lineage markers were quantified by computational cytopathology on immunohistochemistry. mRNA expression analysis of nine lineage markers and 17 immunomodulators was performed by NanoString. I...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: November 2019Source: Human Pathology: Case Reports, Volume 18Author(s): Yuri Noda, Yuko Nakanishi, Kumi Masuda, Masaru YamasakiAbstractSarcomatoid mesothelioma (SM) is the rarest subtype of malignant mesothelioma (MM) with the poorest prognosis. Due to its aggressive nature, early diagnosis and treatment are required for SM, resulting in they significantly improve patient survival. Until now, effusion cytology using ancillary techniques has aided in the early diagnosis of MM, and the cytological findings of the epithelioid component of MM have been well described. However, there has been no detailed cytom...
Source: Human Pathology: Case Reports - Category: Pathology Source Type: research
Abstract Pyridoclax is considered as a promising anticancer drug, acting as a protein-protein interactions disruptor, with potential applications in the treatment of ovarian, lung, and mesothelioma cancers. 18 sensibly selected structural analogs of Pyridoclax were synthesized, and their physico-chemical properties were systematically assessed, and analyzed. Moreover, considering that drug-membrane interactions play an essential role to understand drugs mode of action and eventual toxic effects, membrane models were used to investigate such interactions in the bulk (liposomes) and at the air-water interface. The m...
Source: ChemMedChem - Category: Chemistry Authors: Tags: ChemMedChem Source Type: research
A new report reveals Johnson &Johnson rushed the test results of its iconic baby powder to show it was free of asbestos contamination. The Wall Street Journal reported Sunday that two independent laboratories found no evidence of asbestos in the same recalled lot of baby powder used in the U.S Food and Drug Administration report last month. But evidence shows the quick turnaround on the tests may have impacted results. One of those laboratories, commissioned by J&J after the FDA report, initially found asbestos in the talc sample, but quickly recanted. It told J&J the sample had been contaminated by the air-conditio...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Publication date: Available online 14 November 2019Source: European Journal of Surgical OncologyAuthor(s): Aditi Bhatt, Yutaka Yonemura, Sanket Mehta, Nazim Benzerdjeb, Praveen Kammar, Loma Parikh, Mita Y. Shah, Sakina Shaikh BHMS, Aruna Prabhu, Suniti Mishra, Snita Sinukumar, Vahan Kepenekian, Naoual Bakrin, Guillaume Passot, Olivier GlehenAbstractBackgroundThe aim was to study the patterns of target region (greater omentum, lesser omentum, falciform and umbilical round ligament) involvement in patients undergoing cytoreductive surgery (CRS) from various primary tumors, factors affecting involvement and implications on su...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | CT Scan | Environmental Health | Hospitals | Laparotomy | Mesothelioma | Ovarian Cancer | Ovaries | PET Scan | Study